Zobrazeno 1 - 10
of 285
pro vyhledávání: '"DAOHONG ZHOU"'
Autor:
Xue Yang, Zexuan Liu, Weiwei Tang, Uday P. Pratap, Alexia B. Collier, Kristin A. Altwegg, Rahul Gopalam, Xiaonan Li, Yaxia Yuan, Daohong Zhou, Zhao Lai, Yidong Chen, Gangadhara R. Sareddy, Philip T. Valente, Edward R. Kost, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi
Publikováno v:
Molecular Oncology, Vol 18, Iss 9, Pp 2136-2156 (2024)
Endometrial carcinoma (ECa) is the fourth most common cancer among women. The oncogene PELP1 is frequently overexpressed in a variety of cancers, including ECa. We recently generated SMIP34, a small‐molecule inhibitor of PELP1 that suppresses PELP1
Externí odkaz:
https://doaj.org/article/004752a72a024ab7b87a815d9b033c3e
Autor:
Song Han, Gerik W. Tushoski-Alemán, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Zhiguang Huo, Jonathan Licht, Thomas J. George, Carmen Allegra, Jose G. Trevino, Steven J. Hughes
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 59, Iss , Pp 101070- (2025)
Oncogenic KRAS signaling plays a critical role in pancreatic ductal adenocarcinoma (PDAC) biology. Recent studies indicate that the combination of MEK and BCL-xL inhibition is synthetically lethal and holds promise for some types of solid cancers, ho
Externí odkaz:
https://doaj.org/article/191df517e9ab4a0b927c1c49c80b247d
Autor:
Digant Nayak, Dongwen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A. Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K. Olsen
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved pot
Externí odkaz:
https://doaj.org/article/4bf39db45fce4580a5d76e6623bf229c
Autor:
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-XL and MCL-1. Unfortun
Externí odkaz:
https://doaj.org/article/35172677c9ab498385ddea2d7bbcff21
Autor:
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Publikováno v:
Cells, Vol 13, Iss 6, p 528 (2024)
BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC). Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) induces dose-limiting thrombocytopenia through on-target BCL-xL inhibition in p
Externí odkaz:
https://doaj.org/article/a29e79df61604c65a48287af106a045c
Autor:
Cuiping Zhang, Xiaojing Cui, Yi Liu, Fang Wang, Robert Signer, Kapana Nattamai, Daohong Zhou, Yi Zheng, Hartmut Geiger, Fengyi Wan, Ying Liang
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/7306213419db47d5a4b95623dd5f3604
Autor:
Yannan Jia, Lina Han, Cassandra L. Ramage, Zhe Wang, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and BCL-2 to the von Hippel-Lindau (VHL) E3 ligase, leading to BCLX L/BCL-2 ub
Externí odkaz:
https://doaj.org/article/44723b7d8a04476c9f09a39b30c15fb8
Autor:
Siyao Li, Man J. Livingston, Zhengwei Ma, Xiaoru Hu, Lu Wen, Han-Fei Ding, Daohong Zhou, Zheng Dong
Publikováno v:
JCI Insight, Vol 8, Iss 8 (2023)
Cisplatin is a widely used chemotherapy drug; however, it induces both acute and chronic kidney diseases (CKD) in patients with cancer. The pathogenesis of cisplatin-induced CKD is unclear, and effective renoprotective approaches are not available. H
Externí odkaz:
https://doaj.org/article/311fc1bdb9b946cca4c68b47b28d8638
Autor:
Dejana Braithwaite, Stephen Anton, Supriya Mohile, James DeGregori, Nancy Gillis, Daohong Zhou, Shirley Bloodworth, Marco Pahor, Jonathan Licht
Publikováno v:
Aging and Cancer, Vol 3, Iss 2, Pp 87-94 (2022)
Abstract Background The intersection of cancer and aging is an emerging public health challenge in developed countries because of the aging and expansion of the population. Aims We convened a panel of experts to share their insights on this topic at
Externí odkaz:
https://doaj.org/article/0b07fe03ee8941b28f96ab8e71af1107
Autor:
Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib an
Externí odkaz:
https://doaj.org/article/776b73003bc44789a62395d3ecb0ff21